CROs to profit from large slice of $91bn biotech pie, say analysts

By Dan Stanton

- Last updated on GMT

Related tags Biogen idec

CROs to profit from large slice of $91bn biotech pie, say analysts
Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst firm Jeffries.

At last month’s Society of Toxicology (SOT) meeting in Phoenix, Arizona​, commentators spoke of the strong funding environment for biotech companies contributing to a possible turnaround of the preclinical sector.

However, such investment is also driving growth in the later stage sector according to a survey by analyst firm Jeffries, who – after initially predicting a slowdown - now expects the market to grow 350-400 base points faster in 2014 than in 2013

“During the 12-months ending March, $91B was raised globally, up 44% over the same period one year ago,”​ said David Windley in an analyst note. “Given the type of companies raising capital, much of this should end up in the hands of the CROs.”

Furthermore, such investment is likely to drive outsourced R&D spending – both early and late-stage – for a number of years to come, he continued, adding “this biotech funding creates new core demand,”​ and “not just a shift from internal to outsourced study execution.”

The “strong biotech funding environment”​ was also cited by ISI analyst Ross Muken in a pre-Q1 reporting note as one of “several secular tailwinds boosting fundamentals in the CRO space.”

However, Muken did note the current volatility in public biotech shares meant the effect on CROs was “increasingly debatable.”

Strategic Alliances?

On the whole, Muken was mostly upbeat about the sector, especially on the late-phase side due to its superior visibility and free cash flow potential.

Furthermore, he noted there is an increased push towards the strategic partnership model, supported by speculation from last week’s Partnerships in Clinical Trial’s Conference (PCT) that Biogen Idec was moving to a single-source model and Pfizer would soon add a third CRO to its current alliances with Icon and Parexel.

Whilst Pfizer told this publication​ it was currently “exploring the option of bringing in a third alliance partner,” ​a third third-party it is yet to be announced, though Muken told us he though “Quintiles has a great shot”​ at being selected by the Pharma Giant.

Windley, however, viewed this anecdotal evidence as an indication that CRO share consolidation is slowing, with more vendors seeing a slight re-expansion.

“In those specific examples, we do not believe the changes have a negative revenue impact for the existing vendors near-term,”​ he said. “However, our survey work backs up these anecdotes with additional indicators that could alter the partnership trend that propelled bookings from 2010-12.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more